Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Symbol: 300357.SZ




Market price today

  • 40.7802

    P/E Ratio

  • 1.3803

    PEG Ratio

  • 13.60B

    MRK Cap

  • 0.01%

    DIV Yield

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357-SZ) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO:Mr. Gengxi Hu
Full-time employees:1608
Address:No. 636, Zhiyuan North Road

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and sells pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. It also offers skin care and stem cells series. The company is headquartered in Huzhou, China.

General Outlook

In simple terms, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. has 523.584 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.952% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.368%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.330%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.114% return, is a testament to Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s adeptness in optimizing resource deployment. Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.140%. Furthermore, the proficiency of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. in capital utilization is underscored by a remarkable 0.137% return on capital employed.

Stock Prices

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $24.44, while its low point bottomed out at $23.01. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 300357.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 930.83% gauges short-term asset coverage for liabilities. The quick ratio (888.51%) assesses immediate liquidity, while the cash ratio (635.23%) indicates cash reserves.

Current Ratio930.83%
Quick Ratio888.51%
Cash Ratio635.23%

Profitability Ratios

300357.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 36.99% underscores its earnings before tax deductions. The effective tax rate stands at 14.02%, revealing its tax efficiency. The net income per EBT, 89.20%, and the EBT per EBIT, 100.40%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 36.85%, we grasp its operational profitability.

Pretax Profit Margin36.99%
Effective Tax Rate14.02%
Net Income per EBT89.20%
EBT per EBIT100.40%
EBIT per Revenue36.85%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 9.31, it details the span from stock purchase to revenue. The 9 days it takes to settle debts showcases its creditor relations. Meanwhile, a 6 cash conversion cycle and 281.34% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding889
Days of Inventory Outstanding486
Operating Cycle615.41
Days of Payables Outstanding68
Cash Conversion Cycle548
Receivables Turnover2.81
Payables Turnover5.39
Inventory Turnover0.75
Fixed Asset Turnover1.32
Asset Turnover0.35

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.49, and free cash flow per share, 0.04, depict cash generation on a per-share basis. The cash per share value, 2.26, showcases liquidity position. A payout ratio of 0.37 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.29, offers insight into cash flow relative to sales.

Operating Cash Flow per Share0.49
Free Cash Flow per Share0.04
Cash per Share2.26
Payout Ratio0.37
Operating Cash Flow Sales Ratio0.29
Free Cash Flow to Operating Cash Flow Ratio0.09
Cash Flow Coverage Ratio6.85
Short Term Coverage Ratio11.48
Capital Expenditure Coverage Ratio1.09
Dividend Paid and Capex Coverage Ratio0.75

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 1.48%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.02, we discern the balance between debt and equity financing. The long-term debt to capitalization, 0.69%, and total debt to capitalization, 1.70%, ratios shed light on its capital structure. An interest coverage of 288.49 indicates its ability to manage interest expenses.

Debt Ratio1.48%
Debt Equity Ratio0.02
Long Term Debt to Capitalization0.69%
Total Debt to Capitalization1.70%
Interest Coverage288.49
Cash Flow to Debt Ratio6.85
Company Equity Multiplier1.17

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.71, provides a glimpse into top-line earnings distributed across each share. Net income per share, 0.67, reflects the portion of profit attributed to each share. The book value per share, 3.78, represents the net asset value distributed per share, while the tangible book value per share, 3.51, excludes intangible assets.

Revenue Per Share1.71
Net Income Per Share0.67
Book Value Per Share3.78
Tangible Book Value Per Share3.51
Shareholders Equity Per Share3.78
Interest Debt Per Share0.03
Capex Per Share-0.36

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 10.94%, indicates top-line expansion, while the gross profit growth, 10.54%, reveals profitability trends. EBIT growth, 0.84%, and operating income growth, 0.84%, offer insights into operational profitability progression. The net income growth, 3.19%, showcases bottom-line expansion, and the EPS growth, 3.08%, measures the growth in earnings per share.

Revenue Growth10.94%
Gross Profit Growth10.54%
EBIT Growth0.84%
Operating Income Growth0.84%
Net Income Growth3.19%
EPS Growth3.08%
EPS Diluted Growth3.08%
Dividends per Share Growth25.62%
Operating Cash Flow Growth-0.08%
Free Cash Flow Growth-28.05%
10-Year Revenue Growth per Share438.98%
5-Year Revenue Growth per Share132.38%
3-Year Revenue Growth per Share40.14%
10-Year Operating CF Growth per Share676.59%
5-Year Operating CF Growth per Share126.40%
3-Year Operating CF Growth per Share54.68%
10-Year Net Income Growth per Share475.53%
5-Year Net Income Growth per Share87.41%
3-Year Net Income Growth per Share16.92%
10-Year Shareholders Equity Growth per Share868.60%
5-Year Shareholders Equity Growth per Share147.06%
3-Year Shareholders Equity Growth per Share55.75%
10-Year Dividend per Share Growth per Share29060.24%
5-Year Dividend per Share Growth per Share160.49%
3-Year Dividend per Share Growth per Share44.72%
Receivables Growth11.22%
Inventory Growth-9.94%
Asset Growth13.76%
Book Value per Share Growth14.03%
Debt Growth108.33%
R&D Expense Growth20.58%
SGA Expenses Growth9.15%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 28,025,052,624.9, captures the company's total value, considering both debt and equity. Income quality, 1.07, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.01, gauges operational efficiency, while the research and development to revenue, 11.83%, highlights investment in innovation. The ratio of intangibles to total assets, 8.62%, indicates the value of non-physical assets, and capex to operating cash flow, -52.39%, measures reinvestment capability.

Enterprise Value28,025,052,624.9
Income Quality1.07
Sales General and Administrative to Revenue0.01
Research and Development to Revenue11.83%
Intangibles to Total Assets8.62%
Capex to Operating Cash Flow-52.39%
Capex to Revenue-21.06%
Capex to Depreciation-723.70%
Stock-Based Compensation to Revenue-0.06%
Graham Number7.53
Return on Tangible Assets17.37%
Graham Net Net2.30
Working Capital1,374,381,185
Tangible Asset Value1,837,618,487
Net Current Asset Value1,306,372,615
Average Receivables270,541,499.5
Average Payables6,383,810
Average Inventory51,080,804.5
Days Sales Outstanding116
Days Payables Outstanding68
Days of Inventory On Hand428

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 5.46, and the price to book ratio, 5.46, reflect the market's valuation relative to the company's book value. The price to sales ratio, 13.46, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 536.73, and price to operating cash flows, 45.94, gauge market valuation against cash flow metrics.

Price Book Value Ratio5.46
Price to Book Ratio5.46
Price to Sales Ratio13.46
Price Cash Flow Ratio45.94
Price Earnings to Growth Ratio1.38
Enterprise Value Multiple34.30
Price Fair Value5.46
Price to Operating Cash Flow Ratio45.94
Price to Free Cash Flows Ratio536.73
Price to Tangible Book Ratio14.57
Enterprise Value to Sales31.28
Enterprise Value Over EBITDA59.36
EV to Operating Cash Flow77.79
Earnings Yield1.21%
Free Cash Flow Yield0.59%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 40.780 in 2024.

What is the ticker symbol of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. stock?

The ticker symbol of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. stock is 300357.SZ.

What is company IPO date?

IPO date of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is 2014-01-21.

What is company current share price?

Current share price is 25.970 CNY.

What is stock market cap today?

The market cap of stock today is 13597476454.000.

What is PEG ratio in 2024?

The current 1.380 is 1.380 in 2024.

What is the number of employees in 2024?

In 2024 the company has 1608.